Compare CRDF & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | USAS |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 3.2B |
| IPO Year | 2012 | 2004 |
| Metric | CRDF | USAS |
|---|---|---|
| Price | $1.81 | $6.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $9.63 | $4.08 |
| AVG Volume (30 Days) | 663.7K | ★ 5.8M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | $26.21 |
| Revenue Next Year | N/A | $129.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $1.48 | $0.40 |
| 52 Week High | $4.56 | $10.50 |
| Indicator | CRDF | USAS |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 36.45 |
| Support Level | $1.51 | $0.84 |
| Resistance Level | $2.05 | $10.28 |
| Average True Range (ATR) | 0.12 | 0.61 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 1.96 | 0.84 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.